UBS Group
CNTX icon

UBS Group’s Context Therapeutics CNTX Stock Holding History

UBS Group’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$157K Buy
524,545
+496,362
+1,761% +$245K ﹤0.01% 6903
2026
Q2 		$15.6K Buy
28,183
+21,995
+355% +$44.6K ﹤0.01% 8308
2026
Q1 		$16.2K Buy
6,188
+5,698
+1,163% +$13.3K ﹤0.01% 8081
2025
Q4 		$720 Sell
490
-6,892
-93% -$8.05K ﹤0.01% 9835
2025
Q3 		$7.15K Buy
7,382
+7,012
+1,895% +$5.68K ﹤0.01% 8742
2025
Q2 		$242 Sell
370
-62
-14% -$45 ﹤0.01% 9905
2025
Q1 		$264 Sell
432
-698,697
-100% -$608K ﹤0.01% 9861
2024
Q4 		$734K Buy
699,129
+697,412
+40,618% +$1.21M ﹤0.01% 5560
2024
Q3 		$3.36K Buy
+1,717
New +$3.81K ﹤0.01% 8276
2024
Q1 		– Sell
-9,490
Closed -$10.7K – 9395
2023
Q4 		$10.7K Buy
+9,490
New +$10.2K ﹤0.01% 7425
2023
Q2 		– Sell
-5,767
Closed -$3.24K – 9005
2023
Q1 		$3.24K Buy
5,767
+3,012
+109% +$2.28K ﹤0.01% 8352
2022
Q4 		$1.79K Buy
+2,755
New +$2.97K ﹤0.01% 9790
2022
Q3 		– Sell
-3,627
Closed -$8K – 10404
2022
Q2 		$8K Buy
+3,627
New +$6.8K ﹤0.01% 8291

Other funds holding CNTX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Landscape Capital Management
Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group's CNTX Position: Q3 2026 in Review

UBS Group increased its Context Therapeutics (CNTX) stake by 1,761% in Q3 2026, buying an estimated $245K and bringing the position to 524,545 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #6903.

UBS Group first reported a position in CNTX in Q2 2022 and has held it in 13 quarters since. The position peaked at $734K in Q4 2024. 47 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

  • UBS Group held 524,545 shares of Context Therapeutics worth $157K as of Q3 2026.
  • UBS Group bought 496,362 Context Therapeutics shares in Q3 2026, an estimated $245K.
  • Context Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #6903 holding.
  • UBS Group first reported a position in Context Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • UBS Group's Context Therapeutics position peaked at $734K in Q4 2024.
  • 47 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.